HR2326

The Dietary Guidelines Reform Act of 2025 amends Section 301(a) of the National Nutrition Monitoring and Related Research Act of 1990, changing the frequency of dietary guideline reports from "every five years" to "at least every 10 years." It also mandates that rulemaking requirements under section 553 of title 5, United States Code, apply to the development of these reports, increasing scientific rigor and transparency. This legislative action directly reduces the regulatory burden and uncertainty for food manufacturers. This bill does not involve direct appropriations or funding. The mechanism of impact is regulatory relief. Food manufacturers face fewer mandates for rapid product reformulation and marketing adjustments driven by frequently changing federal health recommendations. This stability allows for longer product lifecycles and more consistent marketing strategies, reducing R&D and compliance costs. Companies with established product lines and significant market share in packaged foods are the primary beneficiaries. Historically, shifts in dietary guidelines have prompted significant industry responses. For example, the 2015-2020 Dietary Guidelines for Americans, which emphasized reduced sugar and saturated fat, led to widespread reformulation efforts across the food industry. While specific market data tied directly to guideline changes is difficult to isolate from broader market trends, companies that successfully adapted or already aligned with new guidelines saw competitive advantages. Conversely, companies heavily reliant on products targeted by new restrictions faced increased costs and potential sales declines. This bill reverses that pressure, favoring stability. Specific winners include large, diversified food and beverage companies that produce a wide range of established products. These companies benefit from reduced pressure to reformulate and can maintain existing product lines with greater confidence. Examples include PepsiCo ($PEP), The Coca-Cola Company ($KO), Mondelez International ($MDLZ), The Kraft Heinz Company ($KHC), and General Mills ($GIS). There are no direct losers from this bill; rather, companies that thrive on rapid innovation driven by shifting health trends may find less impetus for such changes, but this is not a negative impact. This bill has been introduced in the House and referred to the Committee on Agriculture. The next step is committee consideration, including potential hearings and markup sessions. If it passes the committee, it will proceed to a House floor vote. Given the sponsor, Rep. Jackson, Ronny [R-TX-13], and the nature of the bill, it is likely to garner support from industries seeking regulatory predictability. The timeline for passage through both chambers and presidential assent is uncertain but could extend through 2025.